Treatment of Monogenic Diabetes with HNF1B Mutation and Renal Cysts (Renal Cysts and Diabetes Syndrome / MODY5)
Diabetes arising from an HNF1B gene mutation — also known as renal cysts and diabetes syndrome (RCAD) or MODY5 — presents alongside renal developmental disorders such as renal cysts and renal dysplasia. This combination creates a clinically distinct scenario that requires a specific treatment approach, different from other forms of diabetes.
Clinical Scenario
Renal developmental disorders — especially renal cysts and renal dysplasia — are present in almost all persons with HNF1B mutations and constitute the main clinical presentation, even before overt diabetes develops. Alongside the renal phenotype, affected individuals have metabolic features arising from pancreatic involvement that directly determine how their diabetes must be managed.
Treatment Approach (partial)
Conventional oral glucose-lowering agents are not adequately effective in this population due to the underlying metabolic profile. The evidence-based approach involves a specific type of therapy initiated early in the course of disease — the complete structured regimen is available via the link below.
References
DOI: 10.1111/pedi.13426
Renal developmental disorders (especially renal cysts and renal dysplasia) are present in almost all persons with HNF1B mutations or gene deletions and constitute the main presentation in children, even in the absence of diabetes.
In addition to insulin deficiency related to pancreatic hypoplasia, affected persons also show some degree of hepatic IR, which explains why they do not respond adequately to SU treatment and require early insulin therapy.
View source ↗